The Food and Drug Administration’s Approach to Evaluating Nicotine Replacement Therapies: Public Hearing

Washington, DC

FDA White Oak Campus

10903 New Hampshire Ave. 

Bldg 31, Rm 1503A

Washington, DC 

James A. Boiani, Member of the Firm, will speak at a public hearing held by the Food and Drug Administration.

The hearing will discuss the FDA's approach to evaluating the safety and efficacy of nicotine replacement therapy (NRT) products, including how they should be used and labeled.

For more information, please visit